NasdaqGS - Delayed Quote USD

BioNTech SE (BNTX)

92.72 +1.05 (+1.15%)
At close: May 13 at 4:00 PM EDT
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
2,729,600.00
3,819,000.00
17,310,600.00
18,976,700.00
482,300.00
Cost of Revenue
562,900.00
599,800.00
2,995,000.00
2,911,500.00
59,300.00
Gross Profit
2,166,700.00
3,219,200.00
14,315,600.00
16,065,200.00
423,000.00
Operating Expense
2,424,100.00
2,315,000.00
2,011,800.00
1,138,100.00
505,400.00
Operating Income
-257,400.00
904,200.00
12,303,800.00
14,927,100.00
-82,400.00
Net Non Operating Interest Income Expense
471,800.00
349,700.00
29,600.00
-25,800.00
-3,500.00
Other Income Expense
--
-67,800.00
620,700.00
145,100.00
-59,900.00
Pretax Income
146,600.00
1,186,100.00
12,954,100.00
15,046,400.00
-145,800.00
Tax Provision
33,600.00
255,800.00
3,519,700.00
4,753,900.00
-161,000.00
Net Income Common Stockholders
113,000.00
930,300.00
9,434,400.00
10,292,500.00
15,200.00
Diluted NI Available to Com Stockholders
113,000.00
930,300.00
9,434,400.00
10,292,500.00
15,200.00
Basic EPS
0.49
3.87
38.78
42.18
0.06
Diluted EPS
0.47
3.83
37.77
39.63
0.06
Basic Average Shares
240,081.41
240,600.00
243,300.00
244,000.00
253,300.00
Diluted Average Shares
241,589.69
242,700.00
249,800.00
259,700.00
253,300.00
Total Operating Income as Reported
-471,200.00
690,400.00
12,642,700.00
15,283,800.00
-82,400.00
Rent Expense Supplemental
--
--
--
--
2,390.00
Total Expenses
2,987,000.00
2,914,800.00
5,006,800.00
4,049,600.00
564,700.00
Net Income from Continuing & Discontinued Operation
113,000.00
930,300.00
9,434,400.00
10,292,500.00
15,200.00
Normalized Income
165,260.57
983,455.20
8,982,530.40
10,193,251.60
57,130.00
Interest Income
455,400.00
357,600.00
48,500.00
1,500.00
1,600.00
Interest Expense
--
--
16,200.00
5,400.00
2,000.00
Net Interest Income
471,800.00
349,700.00
29,600.00
-25,800.00
-3,500.00
EBIT
-159,600.00
904,200.00
12,303,800.00
14,927,100.00
-143,800.00
EBITDA
30,700.00
1,087,600.00
12,427,100.00
15,002,300.00
-105,100.00
Reconciled Cost of Revenue
562,900.00
599,800.00
2,995,000.00
2,911,500.00
59,300.00
Reconciled Depreciation
190,300.00
183,400.00
123,300.00
75,200.00
38,700.00
Net Income from Continuing Operation Net Minority Interest
113,000.00
930,300.00
9,434,400.00
10,292,500.00
15,200.00
Total Unusual Items Excluding Goodwill
-67,800.00
-67,800.00
620,700.00
145,100.00
-59,900.00
Total Unusual Items
-67,800.00
-67,800.00
620,700.00
145,100.00
-59,900.00
Normalized EBITDA
98,500.00
1,155,400.00
11,806,400.00
14,857,200.00
-45,200.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-15,539.43
-14,644.80
168,830.40
45,851.60
-17,970.00
12/31/2020 - 10/10/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

MRNA Moderna, Inc.
125.67
+7.13%
 
VRTX Vertex Pharmaceuticals Incorporated
429.93
+1.69%
 
AXSM Axsome Therapeutics, Inc.
75.64
+4.33%
 
NVAX Novavax, Inc.
13.11
+47.64%
 
NTLA Intellia Therapeutics, Inc.
25.42
+3.92%
 
BLUE bluebird bio, Inc.
1.0200
-3.77%
 
SAVA Cassava Sciences, Inc.
20.62
+1.93%
 
IOVA Iovance Biotherapeutics, Inc.
10.88
-0.78%
 
CRSP CRISPR Therapeutics AG
55.65
+8.76%
 
CTMX CytomX Therapeutics, Inc.
1.8900
-4.55%